NCT03681704 is a Phase 1 clinical trial of HuangQi Decoction in Diabetic Nephropathy Type 2, sponsored by Shanghai University of Traditional Chinese Medicine.

Who is sponsoring NCT03681704?

NCT03681704 is sponsored by Shanghai University of Traditional Chinese Medicine.

What drugs are being tested in NCT03681704?

Interventions in NCT03681704: HuangQi Decoction, HuangQi Decoction placebo.

What condition does NCT03681704 study?

NCT03681704 studies Diabetic Nephropathy Type 2.

Is NCT03681704 still recruiting?

NCT03681704 is currently completed. Last updated 11 May 2022.

Last reviewed 2022-05-11 · How we verify

NCT03681704

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

the Integrated Traditional Chinese and Western Medicine Treat Early Stage DKD

Completed Phase 1 Last updated 11 May 2022

What this trial tests

Phase 1 trial testing HuangQi Decoction in Diabetic Nephropathy Type 2 in 96 participants. Completed in 31 December 2021.

Timeline

8 November 2018

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Shanghai University of Traditional Chinese Medicine
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	96
Start date	8 November 2018
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	1 location across China

Drugs / interventions tested

HuangQi Decoction — full drug profile →
HuangQi Decoction placebo

Conditions studied

Diabetic Nephropathy Type 2 — all drugs for Diabetic Nephropathy Type 2 →

Sponsor

Shanghai University of Traditional Chinese Medicine

Who can join

Adults 18 to 75, any sex, with Diabetic Nephropathy Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Efficacy and Safety of treatment with Traditional Chinese Medicine HuangQi Decoctions in Patients with early stage of Diabetic Kidney Disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Exploring the immunometabolic potential of Danggui Buxue Decoction for the treatment of IBD-related colorectal cancer.
Zhang Y, Kang Q, He L, Chan KI, et al · · 2024 · cited 8× · PMID 39210410 · DOI 10.1186/s13020-024-00978-y

Verify or expand the search:

Other recruiting trials for Diabetic Nephropathy Type 2

Currently open trials in the same condition.

NCT06586203 — Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes · NA · recruiting
NCT05888909 — Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy · recruiting
NCT06833541 — Research on Gut Microbiota and Metabolomics in Diabetic Kidney Disease · recruiting
NCT04931537 — Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics. · recruiting
NCT04573920 — Atrasentan in Patients With Proteinuric Glomerular Diseases · Phase 2 · active not recruiting

Other Shanghai University of Traditional Chinese Medicine trials

Trials by the same sponsor.

NCT07331740 — Development and Application of a Parenting Anxiety Intervention Program for Young and Middle-Aged Female Breast Cancer P · NA · not yet recruiting
NCT07069049 — Electroacupuncture in the Treatment of Patients Undergoing Transperineal Prostate Biopsy Under Local Anesthesia · NA · not yet recruiting
NCT07245342 — Electroacupuncture for Improving Urinary Incontinence After Radical Prostatectomy · NA · not yet recruiting
NCT06921512 — TCM Daoyin for Anxiety/Depression: Psychological Effects and Biological Mechanisms · NA · recruiting
NCT06690606 — EOCRCPred: an AI Model to Predict Survival in EOCRC Patients After Surgery · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03681704 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai University of Traditional Chinese Medicine
Last refreshed: 11 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03681704.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing